|
1
|
Peterson DE, Koyfman SA, Yarom N,
Lynggaard CD, Ismaila N, Forner LE, Fuller CD, Mowery YM, Murphy
BA, Watson E, et al: Prevention and management of
osteoradionecrosis in patients with head and neck cancer treated
with radiation therapy: ISOO-MASCC-ASCO guideline. J Clin Oncol.
42:1975–1996. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schwartz HC and Kagan AR:
Osteoradionecrosis of the mandible: Scientific basis for clinical
staging. Am J Clin Oncol. 25:168–171. 2002.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Peterson DE, Doerr W, Hovan A, Pinto A,
Saunders D, Elting LS, Spijkervet FK and Brennan MT:
Osteoradionecrosis in cancer patients: The evidence base for
treatment-dependent frequency, current management strategies, and
future studies. Support Care Cancer. 18:1089–1098. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chronopoulos A, Zarra T, Ehrenfeld M and
Otto S: Osteoradionecrosis of the jaws: Definition, epidemiology,
staging and clinical and radiological findings. A concise review.
Int Dent J. 68:22–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Spijkervet FKL, Brennan MT, Peterson DE,
Witjes MJH and Vissink A: Research frontiers in oral toxicities of
cancer therapies: Osteoradionecrosis of the jaws. J Natl Cancer
Inst Monogr. 2019(lgz006)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
de Almeida-Silva LA, Lupp JDS,
Sobral-Silva LA, Dos Santos LAR, Marques TO, da Silva DBR,
Caneppele TMF and Bianchi-de-Moraes M: The incidence of
osteoradionecrosis of the jaws in oral cavity cancer patients
treated with intensity-modulated radiotherapy: A systematic review
and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol.
138:66–78. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aarup-Kristensen S, Hansen CR, Forner L,
Brink C, Eriksen JG and Johansen J: Osteoradionecrosis of the
mandible after radiotherapy for head and neck cancer: Risk factors
and dose-volume correlations. Acta Oncol. 58:1373–1377.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Beaumont S, Bhatia N, McDowell L, Fua T,
McCullough M, Celentano A and Yap T: Timing of dental extractions
in patients undergoing radiotherapy and the incidence of
osteoradionecrosis: A systematic review and meta-analysis. Br J
Oral Maxillofac Surg. 59:511–523. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kojima Y, Otsuru M, Hasegawa T, Ueda N,
Kirita T, Yamada SI, Kurita H, Shibuya Y, Funahara M and Umeda M:
Risk factors for osteoradionecrosis of the jaw in patients with
oral or oropharyngeal cancer: Verification of the effect of tooth
extraction before radiotherapy using propensity score matching
analysis. J Dent Sci. 17:1024–1029. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chieng CY, Davies A, Aziz A, Lowe D and
Rogers SN: Health related quality of life and patient concerns in
patients with osteoradionecrosis. Br J Oral Maxillofac Surg.
59:1061–1066. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Forner LE, Dieleman FJ, Shaw RJ, Kanatas
A, Butterworth CJ, Kjeller G, Alsner J, Overgaard J, Hillerup S,
Hyldegaard O, et al: Hyperbaric oxygen treatment of mandibular
osteoradionecrosis: Combined data from the two randomized clinical
trials DAHANCA-21 and NWHHT2009-1. Radiother Oncol. 166:137–144.
2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lombardi N, Varoni E, Villa G, Salis A and
Lodi G: Pentoxifylline and tocopherol for prevention of
osteoradionecrosis in patients who underwent oral surgery: A
clinical audit. Spec Care Dentist. 43:136–143. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Robard L, Louis MY, Blanchard D, Babin E
and Delanian S: Medical treatment of osteoradionecrosis of the
mandible by PENTOCLO: preliminary results. Eur Ann Otorhinolaryngol
Head Neck Dis. 131:333–338. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Annane D, Depondt J, Aubert P, Villart M,
Géhanno P, Gajdos P and Chevret S: Hyperbaric oxygen therapy for
radionecrosis of the jaw: A randomized, placebo-controlled,
double-blind trial from the ORN96 study group. J Clin Oncol.
22:4893–4900. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Alam DS, Nuara M and Christian J: Analysis
of outcomes of vascularized flap reconstruction in patients with
advanced mandibular osteoradionecrosis. Otolaryngol Head Neck Surg.
141:196–201. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Baumann DP, Yu P, Hanasono MM and Skoracki
RJ: Free flap reconstruction of osteoradionecrosis of the mandible:
A 10-year review and defect classification. Head Neck. 33:800–807.
2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bettoni J, Olivetto M, Duisit J, Caula A,
Testelin S, Dakpé S, Lengele B and Devauchelle B: The value of
reconstructive surgery in the management of refractory jaw
osteoradionecrosis: A single-center 10-year experience. Int J Oral
Maxillofac Surg. 48:1398–1404. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open.
2(e000172)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pankiw M, Brezden-Masley C and Charames
GS: Comprehensive genomic profiling for oncological advancements by
precision medicine. Med Oncol. 41(1)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Milbury CA, Creeden J, Yip WK, Smith DL,
Pattani V, Maxwell K, Sawchyn B, Gjoerup O, Meng W, Skoletsky J, et
al: Clinical and analytical validation of
FoundationOne®CDx, a comprehensive genomic profiling
assay for solid tumors. PLoS One. 17(e0264138)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Notani Ki, Yamazaki Y, Kitada H,
Sakakibara N, Fukuda H, Omori K and Nakamura M: Management of
mandibular osteoradionecrosis corresponding to the severity of
osteoradionecrosis and the method of radiotherapy. Head Neck.
25:181–186. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Prete A, Borges de Souza P, Censi S, Muzza
M, Nucci N and Sponziello M: Update on fundamental mechanisms of
thyroid cancer. Front Endocrinol (Lausanne). 11(102)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhu J, Zhu X, Tu C, Li YY, Qian KQ, Jiang
C, Feng TB, Li C, Liu GJ and Wu L: Parity and thyroid cancer risk:
A meta-analysis of epidemiological studies. Cancer Med. 5:739–752.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Tuttle RM, Leboeuf R and Martorella AJ:
Papillary thyroid cancer: Monitoring and therapy. Endocrinol Metab
Clin North Am. 36:753–778, vii. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang J, Yu F, Shang Y, Ping Z and Liu L:
Thyroid cancer: Incidence and mortality trends in China, 2005-2015.
Endocrine. 68:163–173. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shaha A: Treatment of thyroid cancer based
on risk groups. J Surg Oncol. 94:683–691. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Toraih EA, Elshazli RM, Trinh LN, Hussein
MH, Attia AA, Ruiz EML, Zerfaoui M, Fawzy MS and Kandil E:
Diagnostic and prognostic performance of liquid biopsy-derived
exosomal microRNAs in thyroid cancer patients: A systematic review
and meta-analysis. Cancers (Basel). 13(4295)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sarda AK, Pandey D, Bhalla SA and Goyal A:
Isolated submandibular gland metastasis from an occult papillary
thyroid cancer. Indian J Cancer. 41:89–91. 2004.PubMed/NCBI
|
|
29
|
Davies RJ, Pring M, Aw J, Hughes CW and
Thomas SJ: Isolated submandibular metastasis from a contralateral
thyroid papillary microcarcinoma: An unusual case. Dentomaxillofac
Radiol. 38:546–549. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Radia S, Singh CV and Chamoli P: Right
submandibular gland metastasis from an occult papillary thyroid
cancer. Int J Otorhinolaryngol Head Neck Surg. 4:836–838. 2018.
|
|
31
|
Mittal RP, Yadav RR, Mhashal SK and Mittal
PR: Occult metastatic papillary thyroid carcinoma presenting as
submandibular mass: An unusual case. Int J Head Neck Surg.
9(131)2018.
|
|
32
|
Golant BT, Velez-Perez A, Krishnamurthy S,
Guo M, Mousavi S, Hu MI, Varghese JM, Zafereo ME and Debnam JM:
Thyroid carcinoma metastasizing to the submandibular gland:
Sonographic findings. J Clin Ultrasound. 48:227–230.
2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sunami K, Ichikawa H, Kubo T, Kato M,
Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M,
Matsushita H, et al: Feasibility and utility of a panel testing for
114 cancer-associated genes in a clinical setting: A hospital-based
study. Cancer Sci. 110:1480–1490. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yatabe Y, Sunami K, Goto K, Nishio K,
Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, et
al: Multiplex gene-panel testing for lung cancer patients. Pathol
Int. 70:921–931. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Takahashi M, Ritz J and Cooper GM:
Activation of a novel human transforming gene, ret, by DNA
rearrangement. Cell. 42:581–588. 1985.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tallini G, Asa SL and Fuller GN: RET
oncogene activation in papillary thyroid carcinoma. Adv Anat
Pathol. 8:345–354. 2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wells SA Jr and Santoro M: Targeting the
RET pathway in thyroid cancer. Clin Cancer Res. 15:7119–7123.
2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kato S, Subbiah V, Marchlik E, Elkin SK,
Carter JL and Kurzrock R: RET aberrations in diverse cancers:
Next-generation sequencing of 4,871 patients. Clin Cancer Res.
23:1988–1997. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Takahashi M, Kawai K and Asai N: Roles of
the RET proto-oncogene in cancer and development. JMA J. 3:175–181.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Abdullah MI, Junit SM, Ng KL, Jayapalan
JJ, Karikalan B and Hashim OH: Papillary thyroid cancer: Genetic
alterations and molecular biomarker investigations. Int J Med Sci.
16:450–460. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Bradford D, Larkins E, Mushti SL,
Rodriguez L, Skinner AM, Helms WS, Price LSL, Zirkelbach JF, Li Y,
Liu J, et al: FDA approval summary: Selpercatinib for the treatment
of lung and thyroid cancers with RET gene mutations or fusions.
Clin Cancer Res. 27:2130–2135. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Regua AT, Najjar M and Lo HW: RET
signaling pathway and RET inhibitors in human cancer. Front Oncol.
12(932353)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Thein KZ, Velcheti V, Mooers BHM, Wu J and
Subbiah V: Precision therapy for RET-altered cancers with RET
inhibitors. Trends Cancer. 7:1074–1088. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hadoux J, Elisei R, Brose MS, Hoff AO,
Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, et
al: Phase 3 trial of selpercatinib in advanced RET-mutant medullary
thyroid cancer. N Engl J Med. 389:1851–1861. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhou C, Solomon B, Loong HH, Park K, Pérol
M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, et al:
First-line selpercatinib or chemotherapy and pembrolizumab in RET
fusion-positive NSCLC. N Engl J Med. 389:1839–1850. 2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mulligan LM: RET revisited: Expanding the
oncogenic portfolio. Nat Rev Cancer. 14:173–186. 2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Vodopivec DM and Hu MI: RET kinase
inhibitors for RET-altered thyroid cancers. Therapeutic Advances in
Medical Oncology. 14(17588359221101691)2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hato H, Sakata KI, Sato J, Satoh A,
Hayashi T and Kitagawa Y: Clinical study of treatment methods and
associated factors in mandibular osteoradionecrosis. J Oral Sci.
63:289–291. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Cabanillas ME and Habra MA: Lenvatinib:
Role in thyroid cancer and other solid tumors. Cancer Treat Rev.
42:47–55. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zschäbitz S and Grüllich C: Lenvantinib: A
tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and
RET. Recent Results Cancer Res. 211:187–198. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Bolamperti S, Villa I and Rubinacci A:
Bone remodeling: An operational process ensuring survival and bone
mechanical competence. Bone Res. 10(48)2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Stegen S, van Gastel N and Carmeliet G:
Bringing new life to damaged bone: The importance of angiogenesis
in bone repair and regeneration. Bone. 70:19–27. 2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Mauceri R, Panzarella V, Morreale I and
Campisi G: Medication-related osteonecrosis of the jaw in a cancer
patient receiving lenvatinib. Int J Oral Maxillofac Surg.
48:1530–1532. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Monteiro L, Vasconcelos C, Pacheco JJ and
Salazar F: Photobiomodulation laser therapy in a lenvatinib-related
osteonecrosis of the jaw: A case report. J Clin Exp Dent.
13:e626–e629. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Akashi M, Wanifuchi S, Iwata E, Takeda D,
Kusumoto J, Furudoi S and Komori T: Differences between
osteoradionecrosis and medication-related osteonecrosis of the jaw.
Oral Maxillofac Surg. 22:59–63. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kimura T, Sakata KI, Imamachi K and
Kitagawa Y: Osteoradionecrosis of the jaw suspicious of correlation
with bone-modifying agent treatment: A case report. Med Case Rep
Stud Protoc. 5(e00302)2024.
|
|
57
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Tori M and Shimo T: Long-term efficacy of
lenvatinib for recurrent papillary thyroid carcinoma after
multimodal treatment and management of complications: A case
report. BMC Cancer. 18(698)2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Yamazaki H, Sugino K, Matsuzu K, Masaki C,
Akaishi J, Hames K, Tomoda C, Suzuki A, Uruno T, Ohkuwa K, et al:
Rapid disease progression after discontinuation of lenvatinib in
thyroid cancer. Medicine (Baltimore). 99(e19408)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Toda S, Iwasaki H, Murayama D, Nakayama H,
Suganuma N and Masudo K: Invasive procedures in patients undergoing
treatment with lenvatinib for thyroid cancer. Mol Clin Oncol.
14(81)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Yamazaki H, Masudo K, Kanada S, Inayama Y,
Hayashi H, Fujii Y and Rino Y: Conversion surgery after lenvatinib
treatment for anaplastic thyroid carcinoma: A case report. Surg
Case Rep. 9(38)2023.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Dubbelman AC, Rosing H, Nijenhuis C,
Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G,
Shumaker R, Schellens JH and Beijnen JH: Pharmacokinetics and
excretion of (14)C-lenvatinib in patients with advanced solid
tumors or lymphomas. Invest New Drugs. 33:233–240. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Resteghini C, Locati LD, Bossi P,
Bergamini C, Guzzo M and Licitra L: Do not throw the baby out with
the bathwater: SELECT a personalized, de-escalated lenvatinib
schedule allows response in locally advanced DTC while controlling
major drug-related bleeding. Ann Oncol. 28:2321–2322.
2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Tomlins SA, Hovelson DH, Suga JM, Anderson
DM, Koh HA, Dees EC, McNulty B, Burkard ME, Guarino M, Khatri J, et
al: Real-world performance of a comprehensive genomic profiling
test optimized for small tumor samples. JCO Precis Oncol 5:
PO.20.00472, 2021.
|
|
65
|
Tang W, Hanada K, Motoo Y, Sakamaki H, Oda
T, Furuta K, Abutani H, Ito S and Tsutani K: Budget impact analysis
of comprehensive genomic profiling for untreated advanced or
recurrent solid cancers in Japan. J Med Econ. 26:614–626.
2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Gamboa O, Bonilla CE, Quitian D, Torres
GF, Buitrago G and Cardona AF: Cost-effectiveness of comprehensive
genomic profiling in patients with non-small cell lung cancer for
the colombian health system. Value Health Reg Issues. 39:115–125.
2024.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Subbiah V, Hu MI, Wirth LJ, Schuler M,
Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles
DW, et al: Pralsetinib for patients with advanced or metastatic
RET-altered thyroid cancer (ARROW): A multi-cohort, open-label,
registrational, phase 1/2 study. Lancet Diabetes Endocrinol.
9:491–501. 2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wirth LJ, Brose MS, Subbiah V, Worden F,
Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D,
Deschler-Baier B, et al: Durability of response with selpercatinib
in patients with RET-activated thyroid cancer: Long-term safety and
efficacy from LIBRETTO-001. J Clin Oncol. 42:3187–3195.
2024.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Andreassen PR, Seo J, Wiek C and Hanenberg
H: Understanding BRCA2 function as a tumor suppressor based on
domain-specific activities in DNA damage responses. Genes (Basel).
12(1034)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Wei Q, Gan C, Sun M, Xie Y, Liu H, Xue T,
Deng C, Mo C and Ye T: BRD4: An effective target for organ
fibrosis. Biomark Res. 12(92)2024.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Ichijo R, Kobayashi H, Yoneda S, Iizuka Y,
Kubo H, Matsumura S, Kitano S, Miyachi H, Honda T and Toyoshima F:
Tbx3-dependent amplifying stem cell progeny drives interfollicular
epidermal expansion during pregnancy and regeneration. Nat Commun.
8(508)2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Kaplan J, Lee ZH, Grome L, Yao CMKL,
Mericli AF, Roubaud MS, Largo RD and Garvey PB: Sensory outcomes
for inferior alveolar nerve reconstruction with allograft following
free fibula mandible reconstruction. Plast Reconstr Surg.
152:499e–506e. 2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Takeuchi N, Sawada N, Ekuni D and Morita
M: Oral factors as predictors of frailty in community-dwelling
older people: A prospective cohort study. Int J Environ Res Public
Health. 19(1145)2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
van der Bilt A, Engelen L, Pereira LJ, van
der Glas HW and Abbink JH: Oral physiology and mastication. Physiol
Behav. 89:22–27. 2006.PubMed/NCBI View Article : Google Scholar
|
